ATE389635T1 - Pharmazeutisch wirksame piperidinderivate - Google Patents

Pharmazeutisch wirksame piperidinderivate

Info

Publication number
ATE389635T1
ATE389635T1 AT02729458T AT02729458T ATE389635T1 AT E389635 T1 ATE389635 T1 AT E389635T1 AT 02729458 T AT02729458 T AT 02729458T AT 02729458 T AT02729458 T AT 02729458T AT E389635 T1 ATE389635 T1 AT E389635T1
Authority
AT
Austria
Prior art keywords
pharmaceutically active
piperidine derivatives
active piperidine
derivatives
inhibitors
Prior art date
Application number
AT02729458T
Other languages
English (en)
Inventor
T D Butters
Raymond Dwek
George Fleet
Michael G Orchard
Frances M Platt
Original Assignee
Actelion Pharmaceuticals Ltd
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Univ Oxford filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE389635T1 publication Critical patent/ATE389635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
AT02729458T 2001-01-12 2002-01-11 Pharmazeutisch wirksame piperidinderivate ATE389635T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100889.5A GB0100889D0 (en) 2001-01-12 2001-01-12 Compounds

Publications (1)

Publication Number Publication Date
ATE389635T1 true ATE389635T1 (de) 2008-04-15

Family

ID=9906757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729458T ATE389635T1 (de) 2001-01-12 2002-01-11 Pharmazeutisch wirksame piperidinderivate

Country Status (19)

Country Link
US (3) US20040097551A1 (de)
EP (1) EP1362031B1 (de)
JP (1) JP4313572B2 (de)
KR (1) KR100879651B1 (de)
CN (1) CN1267420C (de)
AT (1) ATE389635T1 (de)
AU (1) AU2002219363B2 (de)
BR (1) BRPI0206433B8 (de)
CA (1) CA2433675C (de)
DE (1) DE60225671T2 (de)
ES (1) ES2304439T3 (de)
GB (1) GB0100889D0 (de)
HU (1) HU229428B1 (de)
IL (1) IL156873A0 (de)
MX (1) MXPA03006185A (de)
PT (1) PT1362031E (de)
RU (1) RU2279425C2 (de)
WO (1) WO2002055498A1 (de)
ZA (1) ZA200305118B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CN1655777A (zh) * 2002-03-13 2005-08-17 尤尼特尔药品公司 雄性避孕的非激素方法
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
CA2544086A1 (en) * 2003-10-29 2005-05-06 Macrozyme B.V. Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
WO2005092334A2 (en) * 2004-03-25 2005-10-06 David Priestman Use of n-substituted imino sugars for appetite suppression
EP1797898A4 (de) * 2004-09-08 2009-09-09 Takeda Pharmaceutical Arzneimittel zur prävention/behandlung von arteriosklerose
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US8975280B2 (en) 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) * 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (de) 2008-10-03 2016-03-30 Genzyme Corporation Glucosylceramidsynthaseinhibitoren vom 2-acylaminopropoanoltyp
EP2889043B1 (de) 2008-12-16 2019-04-10 Genzyme Corporation Synthetische Zwischenprodukte zur Verwendung zur Herstellung von Oligosaccharid-Protein-Konjugate
CN102655746B (zh) * 2009-02-23 2016-08-03 联合治疗公司 亚氨基糖以及治疗病毒性疾病的方法
KR101787434B1 (ko) * 2009-02-24 2017-11-15 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
US8426445B2 (en) * 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
WO2011028779A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
KR101459530B1 (ko) * 2009-09-04 2014-11-07 유나이티드 세러퓨틱스 코오포레이션 폭스바이러스 감염의 치료 방법
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
CA2783405A1 (en) * 2009-12-07 2011-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2394667A1 (de) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vektoren und Sequenzen zur Behandlung von Erkrankungen
EP2785335B8 (de) 2011-11-29 2017-08-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von morbus darier
JP2016513729A (ja) * 2013-03-15 2016-05-16 ユニザー ヴィロロジー，エルエルシー 抗菌化合物
US20160075651A1 (en) * 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
US11306058B2 (en) 2017-06-01 2022-04-19 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
WO2020229968A1 (en) * 2019-05-10 2020-11-19 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
EP4146623A4 (de) * 2020-05-07 2024-05-01 Alectos Therapeutics Inc Nicht-lysosomale glucosylceramidase-inhibitoren und verwendungen davon
JP2023525250A (ja) * 2020-05-07 2023-06-15 アレクトス セラピューティックス インコーポレイテッド 非リソソームグルコシルセラミダーゼ阻害剤及びその使用
EP4201403A1 (de) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
JPH02306962A (ja) 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JPH0324057A (ja) 1989-06-22 1991-02-01 Tosoh Corp ポリヒドロキシピペリジン類及びその製造法
EP0491041A4 (en) 1989-09-07 1993-03-03 Nippon Shinyaku Company, Limited Antiviral drug
WO1992000277A1 (fr) 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US5276120A (en) * 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
JP3506434B2 (ja) 1993-05-05 2004-03-15 ロシュ ダイアグノスティックス ゲーエムベーハー ブレビバクテリウム・ステロリカム由来のコレステロールオキシダーゼ
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
AU732552B2 (en) * 1996-07-15 2001-04-26 Genzyme Corporation Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
EP0983239A1 (de) * 1997-05-06 2000-03-08 Novo Nordisk A/S Neue heterocyclische verbindungen
US6426198B1 (en) * 1997-07-03 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Genes for Niemann-Pick type C disease
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
WO2001007078A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
CN1655777A (zh) * 2002-03-13 2005-08-17 尤尼特尔药品公司 雄性避孕的非激素方法
AU2003248960B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds

Also Published As

Publication number Publication date
DE60225671T2 (de) 2009-04-16
CN1496351A (zh) 2004-05-12
MXPA03006185A (es) 2004-12-03
CA2433675C (en) 2011-03-22
PT1362031E (pt) 2008-06-12
AU2002219363B2 (en) 2007-11-01
HUP0303891A3 (en) 2010-01-28
GB0100889D0 (en) 2001-02-21
BRPI0206433B8 (pt) 2021-05-25
CA2433675A1 (en) 2002-07-18
US20140303208A1 (en) 2014-10-09
WO2002055498A1 (en) 2002-07-18
ZA200305118B (en) 2004-10-01
CN1267420C (zh) 2006-08-02
US20040097551A1 (en) 2004-05-20
ES2304439T3 (es) 2008-10-16
KR100879651B1 (ko) 2009-01-20
BRPI0206433B1 (pt) 2020-01-07
BR0206433A (pt) 2003-12-30
JP2004517869A (ja) 2004-06-17
KR20030081383A (ko) 2003-10-17
US9199935B2 (en) 2015-12-01
IL156873A0 (en) 2004-02-08
DE60225671D1 (de) 2008-04-30
EP1362031A1 (de) 2003-11-19
HU229428B1 (en) 2013-12-30
HUP0303891A2 (hu) 2004-03-29
US20060074107A1 (en) 2006-04-06
RU2279425C2 (ru) 2006-07-10
JP4313572B2 (ja) 2009-08-12
RU2003124756A (ru) 2005-01-10
EP1362031B1 (de) 2008-03-19
US8729099B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
NO20020925D0 (no) N-heterosykliske derivater som NOS-inhibitorer
NO20031001L (no) Polyarylkarboksamider nyttige som lipidsenkende midler
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CY1106358T1 (el) Νεοι δικυκλικοι αναστολεις της ορμονοευαισθητης λιπασης
DK0931788T3 (da) Metalloproteasehæmmere
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
EA200801381A1 (ru) Производные пиримидина
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20054787L (no) Indenderivater som farmasotiske midler
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
SE0400284D0 (sv) Novel compounds
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
SE0103710D0 (sv) Compounds
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
TR200001452T2 (tr) Bifenilamidin türevleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362031

Country of ref document: EP